Activation of the AXL kinase causes resistance to EGFR-targeted therapy in lung cancer.
Zhang Z; Lee JC; Lin L; Olivas V; Au V; LaFramboise T; Abdel-Rahman M; Wang X; Levine AD; Rho JK; Choi YJ; Choi CM; Kim SW; Jang SJ; Park YS; Kim WS; Lee DH; Lee JS; Miller VA; Arcila M; Ladanyi M; Moonsamy P; Sawyers C; Boggon TJ; Ma PC; Costa C; Taron M; Rosell R; Halmos B; Bivona TG; Nature Genetics, 2012, vol. 44, issue 8, p 852, ISSN 15461718. ISBN 15461718.

Full Text Resources Located for this Citation

View article on EBSCOhost(Login required)
View article via CrossRef